Business Context and Reporting Period
Company: ANAVEX LIFE SCIENCES CORP.
Filing Type: Form 8-K (Current Report)
Date of Report: June 3, 2008
Reporting Period: Effective June 3, 2008
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance changes rather than financial performance.
Material Changes
Board Appointment: Effective June 3, 2008, the company appointed David L. Tousley to its board of directors.
- Experience: Mr. Tousley brings over 25 years of senior-level experience in biotech and pharmaceuticals.
- Prior Roles: Former President, COO, and CFO at airPharma, PediaMed Pharmaceuticals, AVAX Technologies, and Pasteur, Merieux, Connaught (Sanofi-Pasteur).
- Key Achievements: Raised over $90 million in debt and equity financings; led business development activities including joint ventures and acquisitions across the U.S., Europe, and Australia.
- Current Board Composition: Cameron Durant, Harvey Lalach, Alison Ayers, and David L. Tousley.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary on financial risks, contingencies, or unusual items. The document serves solely to disclose the appointment of a new director.
Investor Verification Checklist
- Confirm the effective date of David L. Tousley's board appointment (June 3, 2008).
- Review the full news release (Exhibit 99.1) for additional context on the appointment.
- Verify the current board composition against the latest proxy statements or corporate filings.
- Assess Mr. Tousley's specific expertise relative to the company's current development pipeline.